|1.||Schadendorf, Dirk: 5 articles (12/2011 - 03/2002)|
|2.||Federico, Massimo: 4 articles (11/2011 - 12/2005)|
|3.||Kiura, Katsuyuki: 4 articles (06/2011 - 03/2002)|
|4.||Segawa, Yoshihiko: 4 articles (06/2011 - 06/2002)|
|5.||Ueoka, Hiroshi: 4 articles (06/2011 - 03/2002)|
|6.||Tabata, Masahiro: 4 articles (06/2011 - 03/2002)|
|7.||Tanimoto, Mitsune: 4 articles (06/2011 - 03/2002)|
|8.||Eiter, Helmut: 4 articles (05/2009 - 10/2004)|
|9.||Rhomberg, Walter: 4 articles (05/2009 - 10/2004)|
|10.||Ichinose, Yukito: 4 articles (02/2008 - 02/2003)|
|1.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/01/1990 - "Since STS has been proven clinically effective in reducing such side effects, we initiated a study of STS in patients with advanced non-small-cell lung carcinoma who were given a combination of CDDP and vindesine (VDS) systemically. "
01/01/1989 - "In this study, 61 patients with non-small-cell lung carcinoma were randomized to receive either CDDP and vindesine (both given i.v.) with i.v. STS [30 patients, STS(+) group] or CDDP and vindesine without STS [31 patients, STS(-) group]. "
08/01/1987 - "[A phase II study of vindesine for pretreated non-small cell lung cancer]."
09/01/1985 - "A phase II study of vindesine (VDS) was carried out in 21 patients with non-small cell lung cancer (NSCLC). "
09/01/1985 - "Phase II study of vindesine in patients with non-small cell lung cancer."
01/01/1993 - "The efficacy of the association of cisplatinum-mitomycine and vindesine on inoperable non-small cell bronchial cancer has been assessed in a prospective study. "
06/01/1986 - "Phase II study of vindesine in the treatment of pediatric patients with solid tumors: a report from the Childrens Cancer Study Group."
09/01/1983 - "[A cooperative phase II study of vindesine sulfate in patients with solid tumors]."
01/01/1983 - "Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer."
09/01/1980 - "Vindesine trials at Memorial Sloan-Kettering Cancer Center."
|3.||Breast Neoplasms (Breast Cancer)
09/01/1981 - "Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion."
10/01/1984 - "The results--together with the results of other single-agent studies of vindesine summarized in the paper--indicate that the drug is an active agent in advanced breast cancer. "
09/01/1982 - "Vindesine, a new vinca alkaloid, was administered to 20 patients with advanced refractory breast cancer in a phase II trial. "
09/01/1982 - "Phase II study of vindesine in patients with advanced breast cancer."
07/01/1981 - "Phase II study of vindesine in patients with metastatic breast cancer."
|4.||Neoplasm Metastasis (Metastasis)
04/01/2000 - "Ten months later, he developed liver metastases and was treated with vindesine (12 months) and interferon-alpha-2a (30 months) resulting in complete remission which has been maintained for over 10 years. "
06/01/2001 - "Since liver metastasis recurred after initial treatment, chemotherapy consisting of NDP infusion combined with vindesine sulfate (VDS) infusion was performed. "
01/01/2000 - "The diagnosis was established with proctoscopy and biopsy, and a palliative abdominoperineal resection in the presence of lymph node metastases was performed followed by chemotherapy with vindesine. "
07/01/1997 - "For patients with refractory breast cancer, especially with bone metastasis, chemoendocrine therapy containing vindesine might have therapeutic efficacy with low toxicity and favorable quality of life."
01/01/1988 - "[Remarkable effect of vindesine sulfate (VDS) in the treatment of metachronous lung metastasis of esophageal cancer--a case report]."
|5.||Melanoma (Melanoma, Malignant)
10/01/2008 - "Adjuvant treatment with vindesine did not significantly prolong disease free or overall survival in high-risk melanoma patients. "
04/01/2009 - "Adjuvant treatment with vindesine for metastatic melanoma: in response to the study of Eigentler et al. (2008)."
09/01/1984 - "Multicenter phase II trial with 5-day continuous infusion of vindesine in metastatic malignant melanoma."
04/01/1984 - "A phase II study using vindesine (3 mg/m2 by slow intravenous push at seven to 14 day intervals) was carried out in 42 patients with metastatic melanoma. "
04/01/1984 - "Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study."
|7.||Etoposide (VP 16)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|5.||Heterologous Transplantation (Xenotransplantation)